Evidence map›Paper›PMID 36376548›Full record

ArticleArchives of microbiology2022

A new Bacillus Paralicheniformis sp. Tmas-01 as bioreactor for synthesis of Ag/AgCl composite-different effects of biological and Rodamin B dye decolorization, anticancer, genotoxic activity.

Hadis Kordzangeneh, Fereshteh Jookar Kashi

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hadis KordzangenehDepartment of Cell and Molecular Biology, Faculty of Chemistry, University of Kashan, Qotbe-E Ravandi Blvd, Kashan, 8731753153, Isfahan, Iran.ORCID http://orcid.org/0000-0002-6852-0825
Fereshteh Jookar KashiDepartment of Cell and Molecular Biology, Faculty of Chemistry, University of Kashan, Qotbe-E Ravandi Blvd, Kashan, 8731753153, Isfahan, Iran. jookar@kashanu.ac.ir.ORCID http://orcid.org/0000-0002-8332-1269

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Ag/AgCl composite can be synthesized using various chemical, physical, and biological methods. Biosynthesis of nanoparticles is a rapid technology and has advantages over physical and chemical synthesis methods. This research is based on the bacterial formation of silver nanoparticles by bacterial strain Tmas-01. The bacterial strain Tmas-01 was isolated from soil samples and screened for its potential to form Ag/AgCl composite. The formation of Ag/AgCl composite was investigated at the 300-800 nm range using UV-Vis spectrophotometer. Also, the structural and morphological synthesized nanoparticles were characterized using FTIR, SEM-EDS, and XRD. These results showed that Ag/AgCl composite have the SPR absorption peak at 410 nm and a size range of 10-30 nm with a spherical shape. The Ag/AgCl composite exhibited antibacterial and antibiofilm effects against uropathogenic organisms with a range of 5-100%. The results of the genotoxic effects of Ag/AgCl composite by Salmonella typhimurium reverse mutation bioassay (Ames test) indicated which Ag/AgCl composite had no mutation effect. Moreover, Ag/AgCl composite determined an anti-mutagenic effect with a percentage between 97 and 100%. Furthermore, the toxicity of biosynthesized nanoparticles was measured against brine shrimp to evaluate the cytotoxic effect and displayed LC

Indexed as

Metal NanoparticlesSilverAnti-Bacterial AgentsBacillusBacteriaBioreactorsDNA DamagePhylogenyAnti-Bacterial AgentsSilverAg/AgCl compositeAntibacterial activityAntibiofilmCytotoxicityMutagenic

Identifiers

PMID36376548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.